Financial Data and Key Metrics Changes - For the full year 2025, net revenues were $175.1 million, representing a 217% year-over-year growth, with Q4 revenue at $57.6 million, consistent with pre-release estimates [8][16] - Cash operating expenses for Q4 were $50.3 million, better than the guidance of less than $55 million, and full-year cash operating expenses were approximately $284 million, at the low end of the range provided [9][18] - The company reported a loss from operations of approximately $320,000 for Q4, a 95% improvement compared to Q3 [17] Business Line Data and Key Metrics Changes - The sales organization is positioned to deliver growth, with over 1.1 million total prescriptions of VOQUEZNA filled to more than 230,000 patients, indicating strong market penetration [12] - In Q4, 273,000 prescriptions were filled, with 174,000 being covered prescriptions, representing a 21% quarter-over-quarter growth [12] Market Data and Key Metrics Changes - The company targets a market of approximately 65 million patients with gastroesophageal reflux, of which 40% experience inadequate symptom relief from PPIs [12] - The gross margin remained consistent at approximately 87% for both Q4 and the full year [17] Company Strategy and Development Direction - The company aims to achieve operating profitability beginning in Q3 2026 and cash flow positivity in 2027, with a revenue guidance of $320 million-$345 million for 2026 [7][24] - The focus is on enhancing the capital structure, reducing interest expenses, and executing a GI-focused strategy to drive growth [6][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory for 2026, citing strong momentum and a nearly full-strength sales organization [14][15] - The company is not anticipating a fundamental change in broad Medicare coverage but is seeing incremental increases in Medicare prescriptions being covered [52] Other Important Information - The company successfully modified its term loan agreement, extending the maturity date to February 2029 and reducing the interest rate from 12% to 9.85% [19] - The company is exploring potential partnerships and additional products to expand its GI pipeline, although currently focusing on VOQUEZNA and its existing strategy [81][83] Q&A Session Summary Question: Early signals from the strengthened sales force and strategy - Management noted consistent signs of momentum, with a high percentage of gastroenterologists already writing prescriptions for VOQUEZNA and efforts focused on increasing writing frequency [31][32] Question: Dynamics of patients transitioning back to primary care - Management acknowledged an uplift in primary care prescribing volume but emphasized the current focus on gastroenterology [39] Question: Q1 sequential growth expectations - Management indicated typical seasonality effects and acknowledged that Q1 is generally the slowest quarter, but underlying metrics provide confidence for the full year [46][50] Question: Proportions of prescriptions filled through BlinkRx and GoodRx - Management reported that over half of prescriptions are routed through BlinkRx, with a small percentage utilizing GoodRx since its launch in November [60][65] Question: Long-term vision beyond VOQUEZNA - Management is actively considering additional products for the GI pipeline but is currently focused on executing the strategy for VOQUEZNA [80][83]

Core Viewpoint - Marvion Inc. has entered into a Settlement and Share Issuance Agreement to convert HKD 3,950,000 of debt into equity, enhancing its capital structure and supporting growth initiatives [1][2]. Group 1: Strategic Significance of the Arrangement - The Company will issue 15,816,576 shares at a price of $0.0321 per share, based on the seven-day average closing price prior to the effective date [2]. - Converting liabilities to equity reduces debt obligations, thereby strengthening the Company's capital structure and improving financial flexibility [2][3]. - Settling the liability in shares preserves cash resources for ongoing operations and growth initiatives [3]. Group 2: Stakeholder Alignment and Governance - The equity settlement reflects mutual confidence between Marvion and its creditor, reducing immediate cash outflows [3]. - The arrangement received full approval from the Marvion Board of Directors, indicating strong governance and strategic alignment [3]. Group 3: Outlook and Growth Commitment - Marvion is focused on expanding its integrated logistics, warehousing, and supply chain services across Hong Kong and the Asia Pacific region [4]. - The debt settlement reinforces the Company's capital base, supporting ongoing growth plans and positioning it for enhanced operating momentum and long-term value creation for shareholders [4].